Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics to Host 2019 Research & Development Day
LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a
View HTML
Toggle Summary Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Results Expected in 2020 LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc.
View HTML
Toggle Summary Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
LEXINGTON, Mass. , Jan. 15, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to inventing, developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Stephen
View HTML
Toggle Summary Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer
LEXINGTON, Mass. , Jan. 3, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to
View HTML
Toggle Summary Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial
LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed
View HTML
Toggle Summary Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference
LEXINGTON, Mass. , Nov. 28, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-Sponsored Phase 1/2 Clinical Trial of ADX-1612 in Malignant Mesothelioma Raised $67.6 Million, Operations Expected to be Funded Through 2020
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference
LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results
LEXINGTON, Mass. , Nov. 5, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Wednesday, November 14,
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML